Boston Scientific Corporation ($BSX) Stock Forecast: Down 2.3% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation (BSX) is a leading medical technology company specializing in innovative solutions for various medical conditions, particularly in cardiology, electrophysiology, and minimally invasive technologies.

Why is Boston Scientific Corporation going down?

BSX stock is down 2.3% on Dec 8, 2025 15:45

• The bearish movement in BSX stock today could be linked to the negative sentiment following a recent FDA panel vote against a novel shunt implant by Johnson & Johnson for heart failure. This development might have raised concerns about the regulatory landscape for medical device firms, thus influencing the stock price of BSX.
• Although a bullish case is made for BSX focusing on revenue growth and innovation potential, the market sentiment, largely influenced by the FDA panel vote, may have overshadowed these positive aspects.
• Institutional investors showing increased interest in Zimmer Biomet Holdings, Inc. (ZBH) could have diverted attention and financial resources away from BSX, contributing to the downward trend in BSX stock.
• The emergence of Tuodao Medical in China, with a specialty in surgical robot technology, could have further impacted BSX as investors potentially shifted focus towards emerging competitors in the medical technology industry.

BSX Price Chart

BSX Technical Analysis

BSX News

Gamco Investors INC. ET AL Buys 45,164 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Gamco Investors INC. ET AL increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.5%, purchasing 45,164 shares, bringing its total holdings to 245,955 shares valued at approximately $22.43 million. Other institutional investors also adjusted their positions in the medical equipment provider. Analysts currently have a mixed outlook on ZBH, with a consensus "Hold" rating and an average price target of $109.00, although recent target adjustments varied.

https://www.marketbeat.com/instant-alerts/filing-gamco-investors-inc-et-al-buys-45164-shares-of-zimmer-biomet-holdings-inc-zbh-2025-12-08/

Arrowstreet Capital Limited Partnership Purchases 42,196 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Arrowstreet Capital Limited Partnership increased its stake in Zimmer Biomet Holdings, Inc. by 8.9%, acquiring an additional 42,196 shares to bring its total to 514,920 shares valued at approximately $46.97 million. Other institutional investors have also adjusted their positions in the medical equipment provider. Despite mixed analyst sentiment and some firms lowering price targets, the company's recent quarterly earnings beat EPS estimates, though revenue was just below estimates, and it provided FY2025 guidance.

https://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-purchases-42196-shares-of-zimmer-biomet-holdings-inc-zbh-2025-12-06/

FDA panel votes against J&J’s novel shunt implant for heart failure

A U.S. FDA advisory panel has unanimously voted against the risk-benefit profile of Johnson & Johnson’s V-Wave Ventura minimally invasive interatrial shunt for heart failure. Despite the device showing safety in the Relieve-HF pivotal trial, it failed to demonstrate significant clinical benefits compared to a control group, particularly among patients with preserved ejection fraction. Panel members called for more rigorous data and clearer evidence of effectiveness for the novel implant.

https://www.fiercebiotech.com/medtech/fda-panel-votes-against-jjs-novel-shunt-implant-heart-failure

Boston Scientific Corporation (BSX): A Bull Case Theory

This article summarizes a bullish thesis on Boston Scientific Corporation (BSX), highlighting its potential for sustained 8-10% annual revenue growth, significant margin expansion, and double-digit EPS CAGR. Key drivers include structural growth in cardiology, electrophysiology, and minimally invasive technologies, with strong performance from products like Farapulse and Watchman. The company's innovation engine, healthy balance sheet, and strong free cash flow generation are expected to create substantial shareholder value.

https://finviz.com/news/247464/boston-scientific-corporation-bsx-a-bull-case-theory

China-based Tuodao Medical launches with surgical robot tech

Tuodao Medical, a new China-based company, has launched with a focus on developing robotic solutions for intelligent medical care. The company aims to make surgery easier through advanced technologies like AI and high-precision intelligent control, targeting five major surgical robot fields including orthopedics and general surgery. This launch signifies continued innovation in the surgical robotics sector in China, following other recent advancements from companies like Cornerstone Robotics and Ronovo Surgical.

https://www.massdevice.com/tuodao-medical-launches-surgical-robot-china/

Trending Today

Filecoin ($FIL) Crypto Forecast: Up 5.0% Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

Boston Scientific Corporation Price History

24.06.2025 - BSX Stock was down 1.9%

• BSX reported strong Q2 earnings, exceeding estimates and raising its full-year outlook.
• Despite the positive earnings, the stock saw a bearish movement, possibly due to profit-taking by investors who had already factored in the positive news.
• The market's negative reaction may stem from concerns about BSX's ability to maintain its growth momentum in the future, leading some investors to sell off their positions.
• Broader market conditions or sector-specific factors could have influenced the bearish movement in BSX, despite the favorable earnings report.

02.06.2025 - BSX Stock was down 2.5%

• BSX, having outpaced market performance recently, saw a downturn in its stock value.
• Comparisons to peers such as PAHC and MDT may have contributed to investor apprehension about BSX's future trajectory.
• Intensified competition from Medtronic within the MedSurg segment potentially prompted doubts regarding BSX's market stance and growth opportunities.
• Investors appeared to revisit their perspectives on BSX's value proposition, resulting in today's bearish market activity.

10.03.2025 - BSX Stock was up 7.5%

• BSX stock surged 6.8% in a bullish movement today.
• The positive price movement could be attributed to the market's optimism about the company's future growth prospects.
• Despite a recent drop in share price and earnings estimate revisions, investors seem to be confident in BSX's long-term potential, possibly driven by successful product developments or strategic partnerships.
• The overall bullish sentiment towards BSX today may indicate that investors believe in the company's ability to deliver strong financial performance in the coming periods.

22.09.2025 - BSX Stock was up 5.0%

• Boston Scientific (BSX) reported strong Q3 earnings with a 19% growth in EPS, surpassing market expectations. This positive financial performance, along with raising their 2025 sales and EPS outlook, contributed to the bullish movement in the stock.
• The acquisition of Nalu Medical Inc., a maker of minimally invasive devices for chronic pain treatment, for approximately $533 million also boosted investor confidence in Boston Scientific's growth prospects.
• The company's robust cardiovascular performance, driven by innovative products like WATCHMAN FLX Pro and AGENT DCB, is expected to further enhance its earnings potential, attracting more investors to the stock.

02.08.2025 - BSX Stock was up 1.5%

• BSX had a strong bullish movement today, potentially driven by the company's consistent outperformance in the market over the past 5 years, with an average annual return of 20.59%.
• The comparison with other medical stocks may have highlighted BSX's strong performance, attracting investors looking for growth opportunities in the sector.
• Investors might be optimistic about BSX's future prospects, considering its track record of innovation and market leadership in the medical technology industry.

15.09.2025 - BSX Stock was up 4.3%

• BSX closed at $95.41 after a -1.92% shift in the latest trading session, showing a predominantly bullish trend.
• Comparisons with other value stocks like PAHC imply that BSX may offer better value, attracting more investors and positively impacting the market.
• The minor decline in the stock price could be linked to profit-taking following notable gains, yet the outlook for BSX remains optimistic.

08.11.2025 - BSX Stock was down 2.3%

• The bearish movement in BSX stock today could be linked to the negative sentiment following a recent FDA panel vote against a novel shunt implant by Johnson & Johnson for heart failure. This development might have raised concerns about the regulatory landscape for medical device firms, thus influencing the stock price of BSX.
• Although a bullish case is made for BSX focusing on revenue growth and innovation potential, the market sentiment, largely influenced by the FDA panel vote, may have overshadowed these positive aspects.
• Institutional investors showing increased interest in Zimmer Biomet Holdings, Inc. (ZBH) could have diverted attention and financial resources away from BSX, contributing to the downward trend in BSX stock.
• The emergence of Tuodao Medical in China, with a specialty in surgical robot technology, could have further impacted BSX as investors potentially shifted focus towards emerging competitors in the medical technology industry.

06.07.2025 - BSX Stock was down 2.2%

• The bearish movement in BSX today could be attributed to investors comparing the stock with GE HealthCare Technologies (GEHC) and potentially finding more value in the latter.
• The overly optimistic views of Wall Street analysts on BSX might have raised concerns among investors about the stock's actual performance, leading to a sell-off.
• Investors may have also reacted to broader market trends or specific industry news impacting medical product companies, causing a negative sentiment towards BSX in today's trading session.

23.03.2025 - BSX Stock was up 5.5%

• BSX stock demonstrated significant bullish momentum recently.
• The company disclosed Q1 earnings and revenues that exceeded expectations, signaling robust financial results.
• Market participants seem to be responding favorably to the strong performance, displaying trust in Boston Scientific's potential for growth.
• The impressive earnings and revenue figures are likely fueling heightened investor confidence and enthusiasm for the stock, contributing to its current upward trajectory.

23.03.2025 - BSX Stock was up 5.5%

• Boston Scientific Corporation (BSX) raised its annual outlook after reporting strong sales in heart devices in Q1, beating revenue and earnings estimates.
• The company's cardiovascular sales saw significant growth, particularly in cardiology products, which contributed to the overall positive performance.
• The stock price surged as investors reacted positively to the company's robust Q1 earnings and revenue results, leading to an optimistic outlook for the future.
• Boston Scientific's solid product portfolio and financial performance in Q1 2025 have instilled confidence in investors, driving the stock price higher.

10.03.2025 - BSX Stock was down 5.3%

• Analysts view BSX as a promising investment, yet the stock saw a decline, possibly linked to investors capitalizing on profits.
• Following a notable increase in BSX's share price in the previous session, today's drop suggests a shift in market sentiment.
• The stock price of BSX declined by 1.55%, potentially due to investors seizing the opportunity to secure profits following the recent upsurge.

01.09.2025 - BSX Stock was down 3.8%

• The bearish movement in Boston Scientific's stock today could be attributed to profit-taking by investors after a prolonged period of outperformance.
• The comparison between Boston Scientific and Phibro Animal Health in terms of value might have led some investors to shift their focus, causing a temporary dip in BSX stock.
• Market sentiment or broader economic factors could also have played a role in the bearish movement of Boston Scientific's stock today.